Growth Opportunity Growing installed base of Gyrolab systems (xPand and xPlore) and peptide synthesizers (PurePep Chorus, Symphony X, PurePep Sonata+) in biopharmaceuticals suggests cross-sell of kits, reagents, and automation upgrades to existing customers pursuing higher throughput and integrated workflows.

Expansion via HCP Kits Recent and upcoming launches of host cell protein detection kits (HEK293 HCP Type SN and Type CL) provide a ready-made entry point for selling complementary impurity assays, enabling customers to expand assay coverage in biotherapeutics development and manufacturing.

Residual dsRNA Automated Gyrolab assays for residual dsRNA with competitive LOD/LLOQ performance open opportunities to position Gyros as a go-to supplier for critical quality control analytics in RNA-containing biologics and vaccine development.

CRO Partnerships CRO Certification Program signals readiness to formalize collaborations and channel sales through service providers; target CROs and CMOs to broaden adoption of Gyrolab platforms in preclinical and clinical development.

Strategic Collaborations Recent collaborations (BioGenes kits) and ongoing kit expansions create joint selling moments; leverage partnerships to bundle instruments with ready-to-use reagent kits for faster time-to-result and reduced development risk.